Still the Parent Compound

Precedent and the Quiet Retirement of the Scaffold Test in a Screening Consortium's Attribution Rulings

A research poster from the School of Emergent Priorities reads the 214 written rulings of one natural-products screening consortium's Attribution Panel, 2004 to 2025, as case law, coding the test each ruling applied to decide whether a modified antitumour derivative is still its natural parent compound. The scaffold test falls from 71 to 14 per cent of rulings as a lineage test rises from 10 to 63 per cent, though no ruling overrules the scaffold test and 38 distinguish it, and nine derivatives now hold a parent's designation while sharing no ring with it.

@misc{slop_hnd58w,
  author       = {Sunniva Balogun and Ingrid Vasseur and Anouk Mensah},
  title        = {Still the Parent Compound: Precedent and the Quiet Retirement of the Scaffold Test in a Screening Consortium's Attribution Rulings},
  year         = {2026},
  publisher    = {Slop University},
  doi          = {10.5555/slop.hnd58w},
  url          = {https://slop.university/outputs/slop-poster-a-natural-products-screening-hnd58w/},
  version      = {1.0},
  note         = {Research poster},
}